Markets:

Overview

News

Currencies

International

Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

18.76 +0.39 (+2.12%)

Streaming Delayed Price Updated: 10:34 AM EST, Dec 4, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025

August 11, 2025

From Summit Therapeutics

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

July 23, 2025

From Pomerantz LLP

Via GlobeNewswire

3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results ↗

July 22, 2025

Via The Motley Fool

This Healthcare Stock's Revolutionary Drug Could Make Early Investors Rich ↗

July 21, 2025

Via The Motley Fool

3 Monster Stocks in the Making to Buy Right Now ↗

July 21, 2025

Via The Motley Fool

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

July 18, 2025

From Pomerantz LLP

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

July 16, 2025

Via Benzinga

Johnson & Johnson Raises FY25 Forecast, Joins Rigetti Computing, Unity Software, Brighthouse Financial And Other Big Stocks Moving Higher On Wednesday ↗

July 16, 2025

Via Benzinga

SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm

July 14, 2025

From The Schall Law Firm

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT

July 14, 2025

From Pomerantz LLP

Via GlobeNewswire

Why Is AbbVie Stock Trading Higher On Thursday? ↗

July 10, 2025

AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase clinical data.

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

July 10, 2025

From Pomerantz LLP

Via GlobeNewswire

Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug ↗

July 09, 2025

Merck is acquiring Verona Pharma for $10 billion, gaining COPD drug Ohtuvayre as part of its strategy to offset Keytruda's looming patent loss.

Via Benzinga

Topics Intellectual Property

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

July 06, 2025

From Pomerantz LLP

Via GlobeNewswire

NIKE, Datadog And Snap Are Among Top 11 Large Cap Gainers Last Week (June 30-July 4): Are The Others In Your Portfolio? ↗

July 06, 2025

11 best performing large-cap stocks last week, including Symbotic, Nike, First Solar, Datadog, HPE, Summit Therapeutics, Carnival, POSCO, Wynn Resorts, SharkNinja, and Snap

Via Benzinga

2 Soaring Stocks With More Upside Potential to Buy and Hold ↗

July 04, 2025

Via The Motley Fool

Why AstraZeneca Stock Got Thumped on Thursday ↗

July 03, 2025

Via The Motley Fool

Why Summit Therapeutics Stock Soared 8% Higher Today ↗

July 03, 2025

Via The Motley Fool

AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment ↗

July 03, 2025

Via Benzinga

AstraZeneca In Talks To License Summit Therapeutics’ Experimental Lung Cancer Drug: Report ↗

July 03, 2025

While the terms of the partnership agreement are still being negotiated, it could include an upfront payment worth several billion dollars and milestone payments, Bloomberg reported, while noting that...

Via Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

July 01, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

June 30, 2025

Via ACCESS Newswire

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

June 30, 2025

From Summit Therapeutics Inc.

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

June 26, 2025

Via ACCESS Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

June 25, 2025

Via ACCESS Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

June 24, 2025

Via ACCESS Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

June 23, 2025

From Pomerantz LLP

Via GlobeNewswire

Smart Money is Quietly Loading Up On This $160M Oncology Stock — Is Nuvectis Pharma the Next Breakout Biotech? (NASDAQ: NVCT)

June 20, 2025

With clinical catalysts on the horizon and a seasoned biotech insider doubling down, Could Nuvectis Pharma (NASDAQ:NVCT)* Become the Next Summit Therapeutics (NASDAQ: SMMT)?

Via News Direct

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

June 20, 2025

Via ACCESS Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

June 18, 2025

From Pomerantz LLP

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.